Fol. Biol. 2011, 57, 261-267
https://doi.org/10.14712/fb2011057060261
The Influence of Phenothiazine Derivatives on Doxorubicin Treatment in Sensitive and Resistant Human Breast Adenocarcinoma Cells
References
1. , F., Alama, A., Tasso, B., Boido, V., Bruzzo, C., Sparatore F. (2003) Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. Invest. New Drugs 21, 413-420.
<https://doi.org/10.1023/A:1026295017158>
2. Bartosz, G. (1997) Fighting for survial. Wiedza i Życie 11. (in Polish)
3. , A., Meli, M., Gobbi, S., Rampa, A., Tolomeo, M., Dusonchet, L. (2008) Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives. Bioorg. Med. Chem. 16, 6474-6482.
<https://doi.org/10.1016/j.bmc.2008.05.040>
4. , C. F., Motten, A. G., Buettner, G. R. (1985) Photoinduced free radicals from chloropromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Envir. Health Persp. 64, 103-110.
<https://doi.org/10.1289/ehp.8564103>
5. , M., Fojo, T., Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284.
<https://doi.org/10.1038/nrc1590>
6. , W. N., Pierson, N. R. (1990) Comparison of the efficacy of phenothizine and bisquinalidinium calmodulin antagonist against multidrug-resistant P388 cell lines. Cancer Res. 50, 1165-1169.
7. , A. B., Wesołowska, O., Motohashi, N., Molnár, J., Michalak, K. (2003) New phenothiazine-type multidrug resistance modifiers: anti-MDR activity versus membrane perturbing potency. Biochem. Biophys. Res. Commun. 304, 260-265.
<https://doi.org/10.1016/S0006-291X(03)00580-1>
8. , O., Molnar, A., Butterworth, T. S., Butaye, P., Kolmos, H. J., Christensen, J. B., Kristiansen, J. E. (2005) In vitro activity of phenothiazine derivatives in Enterococcus faecalis and Enterococcus faecium. Basic Clin. Pharmacol. Toxicol. 96, 33-36.
<https://doi.org/10.1111/j.1742-7843.2005.pto960105.x>
9. , K., Szyda, A., Kiełbasiński, M., Duś, D., Podolak-Dawidziak, M. (2005) Clinical implications of multidrug resistance in cancer. Onkol. Prakt. Klin. 1, 18-26. (in Polish)
10. , K., Hendrich, A. B. (2002) The role of cell membrane lipids in the phenomenon of multidrug resistance and its modulation. Post Bioch. 48, 208-219. (in Polish)
11. , N., Kawase, M., Saito, S., Kurihara, T., Satoh, K., Nakashima, H., Arakaki, R., Sakagami, H., Molnar, J. (2000) Synthesis and biological activity of N-acylphenothiazines. Int. J. Antimicrob. Agents 14, 203–207.
<https://doi.org/10.1016/S0924-8579(99)00156-9>
12. , N., Kawase, M., Molnar, J., Ferenczy, L., Wesolowska, O., Hendrich, A. B., Bobrowska-Hägerstrand, M., Hägerstrand, H., Michalak, K. (2003) Antimicrobial activity of N-acylphenothiazines and their influence on lipid model membranes and erythrocyte membranes. Arzneim. Forsch. Drug. Res. 53, 590–599.
13. , M., Mehrgan, H., Hadji-nejad, S. (2010) Enhancement of vancomycin activity by phenothiazines against vancomycin-resistant Enterococcus faecium in vitro. Basic Clin. Pharmacol. Toxicol. 107, 676-679.
<https://doi.org/10.1111/j.1742-7843.2010.00558.x>
14. , J. E. (1984) The photodynamic effect of chlorpromazine, promazine, and hematoporphyrin on lens protein. Invest. Ophthalmol. Vis. Sci. 25, 746-750.
15. , H. K. (2007) Thioridazine: resurrection as an antimicrobial agent? Br. J. Clin. Pharmacol. 64, 566-574.
<https://doi.org/10.1111/j.1365-2125.2007.03021.x>
